Allena Pharmaceuticals, Inc. ALNA
0.08 0.00 (+0.00%)
At closeSep 7, 2022, 4:00 PM EDT
0.06 Day range 0.1459
52-week range unavailable
- Shares out
- 122.08M
- Forward P/E
- -1.07
- Volume
- 252.31M
- Open
- 0.0641
- Previous close
- 0.075
- Day's range
- 0.06 – 0.1459
- Beta
- 1.15
- Analysts
- Hold
- Price target
- 4.00 (+5233.3%)
- Earnings date
- Aug 15, 2022
No chart data for this range yet.
Key statistics
- Enterprise value
- 11.43M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.14
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -33.50M
- Total cash
- 6.59M
- Total debt
- 5.28M
- Return on equity
- -541.02%
- Short % of float
- 8.54%
- 50-day average
- 0.124116
- 200-day average
- 0.276548
Analyst view
Consensus: hold
Hold
Price target (mean) 4.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 15, 2022
Expected Aug 15, 2022. Consensus EPS estimate -0.05.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 15, 2022 | Jun 1, 2022 | -0.06 | — | — | — |
| May 16, 2022 | Mar 1, 2022 | -0.20 | — | — | — |
| Apr 5, 2022 | Dec 1, 2021 | -0.17 | — | — | — |
| Nov 10, 2021 | Sep 1, 2021 | -0.18 | — | — | — |
| Aug 10, 2021 | Jun 1, 2021 | -0.20 | — | — | — |
| May 11, 2021 | Mar 1, 2021 | -0.21 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 22, 2022 | B. Riley Securities | down | Buy | Neutral |
| Mar 21, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Mar 21, 2022 | Ladenburg Thalmann | down | Buy | Neutral |
| Jun 1, 2020 | HC Wainwright & Co. | init | — | Buy |
| Mar 18, 2020 | B. Riley FBR | main | — | Buy |
| Mar 13, 2020 | B. Riley FBR | main | — | Buy |
About Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- allenapharma.com
News
Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday 
Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session 
Hot Penny Stocks to Watch Before Market Open on July 29th 
Alibaba, Zoom Video And 76 Biggest Movers From Yesterday 
Why These Casino Stocks Are Moving Lower, Here's 45 Stocks Moving In Monday's Mid-Day Session 
What to Know About Buying Penny Stocks on July 7th - Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday
Tesla, Ra Medical Systems And 51 Stocks Moving In Tuesday's Mid-Day Session 
Why Shares Of Allena Pharmaceuticals Are Skyrocketing Today 
ALNA Stock Alert: What to Know as Allena Pharmaceuticals Soars 200%
Your note
Sign in to keep a note on ALNA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BESSEMER VENTURE PARTNERS TRUST | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 5, 2017 | 0 |
| BRENNER LOUIS M.D. | Chief Executive Officer | Sale | Nov 14, 2021 | 328,904 |
| FHM VI, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 5, 2017 | 0 |
| HBM BIOCAPITAL II, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 5, 2017 | 1,638,330 |
| TEPPER ROBERT I | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 5, 2017 | 0 |
| THIRD ROCK VENTURES II L P | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 5, 2017 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| TRV GP II, LLC | 2.29% | 2,790,964 | 209.32K | Jun 29, 2022 |
| Vanguard Group, Inc. (The) | 2.20% | 2,682,145 | 201.16K | Jun 29, 2022 |
| Acadian Asset Management. LLC | 1.02% | 1,250,988 | 93.82K | Jun 29, 2022 |
| Frazier Management LLC | 0.95% | 1,019,288 | 76.45K | Mar 30, 2022 |
| Geode Capital Management, LLC | 0.32% | 386,352 | 28.98K | Jun 29, 2022 |
| Two Sigma Securities, LLC | 0.29% | 357,044 | 26.78K | Jun 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.62% | 1,972,415 | 147.93K | Jun 29, 2022 |
| Vanguard Extended Market Index Fund | 0.56% | 681,160 | 51.09K | Jun 29, 2022 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.15% | 177,952 | 13.35K | Jul 30, 2022 |
| Fidelity Extended Market Index Fund | 0.15% | 183,607 | 13.77K | Jun 29, 2022 |
| iShares Micro Cap ETF | 0.11% | 122,654 | 9.20K | May 30, 2022 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.10% | 106,800 | 8.01K | Mar 30, 2022 |